Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0042-1743508
Brief Communication

Outcomes of Allogeneic Stem Cell Transplant in Chronic Myeloid Leukemia - Blast Phase: A Single-center Experience from South India

Thejeswar Nakka 
1   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
,
Arnab Bhattacherjee
1   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
,
Narendran Krishnamoorthi
1   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
,
Divya Bala Tumathy
1   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
,
Sindhu Dahagama
1   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
,
Biswajit Dubashi 
1   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
,
Prasanth Ganesan 
1   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
,
Smita Kayal 
1   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

The blast phase (BP) is challenging to treat and leads to inferior survival in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplant (AlloSCT) is the only curative option for CML-BP. We are sharing our experience of AlloSCT in seven patients with CML-BP who underwent transplants during the period from January 2017 to December 2019. Three patients each had myeloid-BP, lymphoid-BP, and one patient had mixed phenotypic BP. Donors were matched siblings in four, mismatched siblings in one, and haploidentical in two. All patients received peripheral blood stem cell grafts. The median CD34+ dose was 7.6 (range: 6.6–8.9) × 106 cells/kg. Neutrophil engraftment was observed at a median of 15 (10–20) days and platelet engraftment at 19 days (10–22). At a median follow-up of 24 months, the 2-year leukemia-free survival (LFS) and overall survival (OS) were 43% and 57%, respectively. Transplant-related, non-relapse mortality was observed in three patients. AlloSCT results in promising survival for carefully selected patients of CML-BP, especially with a matched sibling donor.

Keywords

chronic myeloid leukemia blast phase - allogeneic hematopoietic stem cell transplant - survival

* These authors contributed equally to this work.


Ethics Approval

Institute Ethics Committee approval was taken before the commencement of the study.


Consent to Participate

Waiver of consent was granted for the retrospective data and analysis.


Author's Contributions

Study conceptualization and methodology: TN, AB, SK, BD, and PG. Data collection and analysis: TN, AB, NK, SD, DBT, and SK. Manuscript writing: TN, AB, SK, NK, DBT, and BD. Review and editing: SK, BD, SD, and PG. Final approval of manuscript: all authors.




Publication History

Article published online:
28 November 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Arber DA, Orazi A, Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20) 2391-2405
    Search in Google Scholar
  • 2 Saußele S, Silver RT. Management of chronic myeloid leukemia in blast crisis. Ann Hematol 2015; 94 (Suppl. 02) S159-S165
    CrossrefPubMedSearch in Google Scholar
  • 3 Kantarjian HM, Hughes TP, Larson RA. et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia 2021; 35 (02) 440-453
    CrossrefPubMedSearch in Google Scholar
  • 4 Guilhot F, Chastang C, Michallet M. et al; French Chronic Myeloid Leukemia Study Group. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997; 337 (04) 223-229
    CrossrefPubMedSearch in Google Scholar
  • 5 Long-term follow-Up of the italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Blood 1998; 92 (05) 1541-1548
    CrossrefPubMedSearch in Google Scholar
  • 6 Hochhaus A, Baccarani M, Silver RT. et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020; 34 (04) 966-984
    CrossrefPubMedSearch in Google Scholar
  • 7 Khoury HJ, Kukreja M, Goldman JM. et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant 2012; 47 (06) 810-816
    CrossrefPubMedSearch in Google Scholar
  • 8 Radujkovic A, Dietrich S, Blok H-J. et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a retrospective study by the EBMT chronic malignancies working party. Biol Blood Marrow Transplant 2019; 25 (10) 2008-2016
    CrossrefPubMedSearch in Google Scholar
  • 9 Jiang H, Xu LP, Liu DH. et al. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. Bone Marrow Transplant 2014; 49 (09) 1146-1154
    CrossrefPubMedSearch in Google Scholar
  • 10 Thota NK, Gundeti S, Linga VG, Coca P, Tara RP. Raghunadharao. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis. Indian J Cancer 2014; 51 (01) 5-9
    CrossrefPubMedSearch in Google Scholar
  • 11 Passweg JR, Baldomero H, Basak GW. et al; European Society for Blood and Marrow Transplantation (EBMT). The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplant 2019; 54 (10) 1575-1585
    CrossrefPubMedSearch in Google Scholar
  • 12 Ganesan P, Ganesan TS, Radhakrishnan V. et al. Chronic myeloid leukemia: long-term outcome data in the imatinib era. Indian J Hematol Blood Transfus 2019; 35 (01) 37-42
    CrossrefPubMedSearch in Google Scholar
  • 13 Ganesan P, Kumar L. Chronic myeloid leukemia in India. J Glob Oncol 2016; 3 (01) 64-71
    CrossrefPubMedSearch in Google Scholar
  • 14 Yanamandra U, Malhotra P. CML in India: are we there yet?. Indian J Hematol Blood Transfus 2019; 35 (01) 1-2
    CrossrefPubMedSearch in Google Scholar
  • 15 Kulkarni U, George B. Access to hematopoietic stem-cell transplantation in India. J Postgrad Med 2019; 65 (01) 1-4
    CrossrefPubMedSearch in Google Scholar
  • 16 Lübking A, Dreimane A, Sandin F. et al. Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. Bone Marrow Transplant 2019; 54 (11) 1764-1774
    CrossrefPubMedSearch in Google Scholar
  • 17 Parthiban SK, Nayak L, Punatar S. et al. Allogeneic stem cell transplantation in chronic myeloid leukemia in era of tyrosine kinase inhibitors-a single center experience from India. Biol Blood Marrow Transplant 2019; 25: S103
    CrossrefSearch in Google Scholar
  • 18 Niederwieser C, Morozova E, Zubarovskaya L. et al. Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML. Bone Marrow Transplant 2021; 56 (11) 2834-2841
    CrossrefPubMedSearch in Google Scholar
  • 19 Saussele S, Lauseker M, Gratwohl A. et al; German CML Study Group. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115 (10) 1880-1885
    CrossrefPubMedSearch in Google Scholar
  • 20 Raj R, Aboobacker FN, Yadav SP. et al. Multicenter outcome of hematopoietic stem cell transplantation for primary immune deficiency disorders in India. Front Immunol 2021; 11: 606930
    CrossrefPubMedSearch in Google Scholar
  • 21 Ma YR, Huang XJ, Xu ZL. et al. Transplantation from haploidentical donor is not inferior to that from identical sibling donor for patients with chronic myeloid leukemia in blast crisis or chronic phase from blast crisis. Clin Transplant 2016; 30 (09) 994-1001
    CrossrefPubMedSearch in Google Scholar
  • 22 DeFilipp Z, Ancheta R, Liu Y. et al. Maintenance tyrosine kinase inhibitors following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia: a Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant 2020; 26 (03) 472-479
    CrossrefPubMedSearch in Google Scholar
  • 23 DeFilipp Z, Langston AA, Chen Z. et al. Does post-transplant maintenance therapy with tyrosine kinase inhibitors improve outcomes of patients with high-risk Philadelphia chromosome-positive leukemia?. Clin Lymphoma Myeloma Leuk 2016; 16 (08) 466-471.e1
    CrossrefPubMedSearch in Google Scholar